Ludzkie koronawirusy - autor: Krzysztof Pyrć z Zakładu Mikrobiologii, Wydział Biochemii, Biofizyki i Biotechnologii, Uniwersytet Jagielloński, Kraków

Zastanawiasz się, jak wydać pracę doktorską, habilitacyjną lub monografię? Chcesz dokonać zmian w stylistyce i interpunkcji tekstu naukowego? Nic prostszego! Zaufaj Wydawnictwu Borgis – wydawcy renomowanych książek i czasopism medycznych. Zapewniamy przede wszystkim profesjonalne wsparcie w przygotowaniu pracy, opracowanie dokumentacji oraz druk pracy doktorskiej, magisterskiej, habilitacyjnej. Dzięki nam nie będziesz musiał zajmować się projektowaniem okładki oraz typografią książki.

Poniżej zamieściliśmy fragment artykułu. Informacja nt. dostępu do pełnej treści artykułu tutaj
© Borgis - Postępy Nauk Medycznych 4/2012, s. 343-346
Tomasz Drewa1, 2, Jan Adamowicz2, *Piotr L. Chłosta1, 3, 4
Krążące komórki nowotworowe guzów litych – klucz do nowej klasyfikacji stopnia zaawansowania raków układu moczowo-płciowego
Circulating tumour cells of solid tumours – a key to the novel clinical staging of genito-urinary neoplasms
1Department of Urology, Holy Cross Cancer Centre Kielce
Head of the Dept.: Prof. Piotr L. Chłosta, MD, PhD
2Department of Tissue Engeneering Collegium Medicum Nicolaus Copernicus University, Bydgoszcz
Head of the Dept.: Prof. Tomasz Drewa, MD, PhD
3Department of Urology, Medical Centre of Postgraduate Education Warsaw
Head of the Dept.: Prof. Andrzej Borówka, MD, PhD
4Department of Health Science, Jan Kochanowski University, Kielce
Streszczenie
Opracowanie zawiera współczesne poglądy na temat oznaczania liczby krążących we krwi komórek nowotworowych (CTC) u chorych na raka nerkowokomórkowego, jako potencjalnego narzędzia diagnostycznego, które pozwoli na dokładniejszą ocenę stopnia zawansowania choroby i monitorowania efektów leczenia. Stosując obecne metody diagnostyczne nie potrafimy wyodrębnić grupy pacjentów szczególnie narażonych na wystąpienie przerzutów. Oznaczanie liczby krążących we krwi pacjentów CTC może stać przydatnym narzędziem diagnostycznym, które pozwoli na dokładniejszą ocenę stopnia zawansowanie choroby i monitorowanie efektów leczenia. Bardzo kusząca jest wizja wprowadzenia do diagnostyki przesiewowej i oceny skuteczności leczenia Liquid biopsy, która pozwala na szybkie wykrycie nowotworu na podstawie badania krwi.
Summary
This is a current review on the circulating tumour cells (CTC) in patients with renal cell carcinoma as a potential diagnostic tool that will allow for more accurate assessment of advanced disease and the monitoring of treatment effects. Using current diagnostic methods, we are still unable to identify patients especially prone to metastases. Assaying for levels of CTC may become a useful diagnostic tool, which will help to assess disease stage with more accuracy as well as monitor treatment outcomes. The introduction of “liquid biopsy”, for screening and treatment monitoring, forms a very attractive outlook, where cases could be easily found by a blood test.
Introduction
Circulating Tumour Cells (CTC) are a population of cells that have detached from the tumour mass and are able to disseminate via the vascular system and create metastatic foci in the body (1). Initially, the immune system eliminates the circulating cancer cells from the bloodstream, but over time, the cells remain there for longer periods and become identifiable. The first published report of circulating tumour cells dates back to 1869 (2).
Prospective studies have demonstrated the effectiveness of identifying and quantifying CTCs in the prediction of malignant tumour treatment outcomes, including cancers of the breast, colon and prostate (3). Currently, intensive research is conducted on the importance of CTC in the biology and therapy of renal cell carcinoma (RCC) and transitional cell carcinoma (TCC). CTCs can be isolated from patients’ blood in the course of most cancers due to the ease of identification of the epithelial phenotype of the cancer. The presence of such cells in the blood coexists with micrometastases, which are clinically silent, and/or precedes the clinical emergence of metastases (4). CTCs are suspected of being instrumental for dissemination of the cancer during surgery, which involves mechanical manipulation and traumatisation of the primary tumour (5).
The circulating cells acquire properties of mesechymal cells, i.e. they are able to function independently. This is known as Epithelial to Mesenchymal Transition (EMT) (6). As a result of changes in their adhesion molecules, the cells separate from the primary cell population and gain the ability to migrate independently within the extracellular matrix and, eventually, outside it (7). The reverse process, known as Mesenchymal to Epithelial Transition (MET), is one of the most important stages of the development of cancer metastases. Armstrong et al. demonstrated that 80% of circulating cells of prostate or breast cancer express mesenchymal and epithelial markers (8). The authors suggested that the ratio of these markers could be a valuable prognostic parameter.
Circulating cancer cells are gradually gaining importance in clinical medicine. Many studies have especially been published on the subject of prostate cancer, where authors underscore the potential role of CTC in the prediction of survival and treatment outcomes. The presence of CTC in the patient’s bloodstream is consistent with disease that is refractory to a given treatment, which therefore requires modification (9). It has been demonstrated in an animal model that approximately 10 CT cells are sufficient to develop a new tumour in the case of renal or prostate cancer (10). Identifying CTC may in future help to discern patients who, according to standard diagnostic methods, are not qualified to undergo further radical treatment due to unfavourable prognosis regarding cure (11).
The isolation and identification of CTC is a challenge for the biotechnological industry. The main issue remains the small number of cells available for study. Normally, blood is drawn in samples of 5 to 10 ml. In a majority of cancers, the available methods are able to identify no less than 10 CTC in 1 ml of blood (12). These data regard cut-off thresholds, hence they cast doubt on experimentally applied norms. Moreover, current diagnostic methods do not allow for identification of CTCs in frozen or preserved blood. This excludes potential retrospective studies, which would certainly accelerate the wide introduction of CTC-based assays into clinical practice.
CellSearch is currently the only system with FDA (Food and Drug Administration, USA) approval for use in determining the number of circulating cancer cells (13). Nonetheless, many new devices for isolating CTC have been presented. Clinical trials are under way to assess the effectiveness of electric biosensors used to rapidly identify CTC in a small volume of blood (14,15). Progress in the isolation and identification of CTC, as well as the understanding of the value of CTC in the prevention and treatment of solid tumours, may in future allow for a “liquid biopsy”, which would identify CTC in the patient’s blood sample and help to plan individualised treatment (16).
Prostate cancer
The number of identified CTC in prostate cancer patients may in the near future become a valuable parameter used to assess the disease stage and improve treatment outcomes. In a clinical study, Stott et al. demonstrated that on average approximately 100 CTCs were found in patients with prostate cancer. The number of CTC fell in all patients on the first day following radical prostatectomy (17).

Powyżej zamieściliśmy fragment artykułu, do którego możesz uzyskać pełny dostęp.

Płatny dostęp do wszystkich zasobów Czytelni Medycznej

Aby uzyskać płatny dostęp do pełnej treści powyższego artykułu oraz WSZYSTKICH około 7000 artykułów Czytelni, należy wprowadzić kod:

Kod (cena 30 zł za 30 dni dostępu) mogą Państwo uzyskać, przechodząc na tę stronę.
Wprowadzając kod, akceptują Państwo treść Regulaminu oraz potwierdzają zapoznanie się z nim.

Piśmiennictwo
1. Chen BT, Loberg RD, Neeley CK et al.: Preliminary study of immunomagnetic quantification of circulating tumor cells in patients with advanced disease. Urology 2005; 65: 616-21.
2. Elshimali YI, Grody WW: The clinical significance of circulating tumor cells in the peripheral blood. Diagn Mol Pathol 2006; 15: 187-94.
3. Ghossein RA, Bhattacharya S: Molecular detection and characterization of circulating tumor cells and micrometastases in prostatic, urothelial, and renal cell carcinomas. Semin Surg Oncol 2001; 20: 304-11.
4. Hayes DF, Smerage JB: Circulating tumor cells. Prog Mol Biol Transl Sci 2010; 95: 95-112.
5. Negin BP, Cohen SJ Circulating tumor cells in colorectal cancer: past, present, and future challenges. Curr Treat Options Oncol 2010; 11: 1-13.
6. Krebs MG, Hou JM, Sloane R et al.: Analysis of Circulating Tumor Cells in Patients with Non-small Cell Lung Cancer Using Epithelial Marker-Dependent and Independent Approaches. J Thorac Oncol 2011 Dec 14.
7. Bonnomet A, Syne L, Brysse A et al.: A dynamic in vivo model of epithelial-to-mesenchymal transitions in circulating tumor cells and metastases of breast cancer. Oncogene 2011; 28.
8. Armstrong AJ, Marengo MS, Oltean S et al.: Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Mol Cancer Res 2011; 9: 997-1007.
9. Kruck S, Gakis G, Stenzl A: Disseminated and circulating tumor cells for monitoring chemotherapy in urological tumors. Anticancer Res 2011; 31: 2053-7.
10. Yu SR, Wei J, Qian XP, Liu BR. Circulating tumor cells and individualized chemotherapy. Ai Zheng 2000; 28: 1225-32.
11. Dotan E, Cohen SJ, Alpaugh KR, Meropol NJ: Circulating tumor cells: evolving evidence and future challenges. Oncologist 2009; 14: 1070-82.
12. Hossein RA, Bhattacharya S, Rosai J: Molecular detection of micrometastases and circulating tumor cells in solid tumors. Clin Cancer Res 1999; 5 (8): 1950-60.
13. FDA Clears Cellsearch™ Circulating Tumor Cell Test For Monitoring Metastatic Prostate Cancer Patients http://www.medicalnewstoday.com
14. Chung YK, Reboud J, Lee KC et al.: An electrical biosensor for the detection of circulating tumor cells. Biosens Bioelectron 2011; 26: 2520-6.
15. Stakenborg T, Liu C, Henry O et al.: Automated genotyping of circulating tumor cells. Expert Rev Mol Diagn 2010; 10: 723-9.
16. Pachmann K, Camara O, Kroll T et al.: Efficacy control of therapy using circulating epithelial tumor cells (CETC) as “liquid biopsy”: trastuzumab in HER2/neu-positive breast carcinoma. J Cancer Res Clin Oncol 2011; 137: 1317-27.
17. Scott SL, Lee RJ, Nagrath S et al.: Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med 2010; 31: 23-25.
18. de Bono JS, Scher HI, Montgomery RB et al.:Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008; 14: 6302-9.
19. Morgan TM, Lange PH, Porter MP et al.: Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence. Clin Cancer Res 2009; 15: 677-83.
20. Moreno JG, Miller MC, Gross S et al.: Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology 2005; 65: 713-8.
21. Okegawa T, Nutahara K, Higashihara E: Prognostic significance of circulating tumor cells in patients with hormone refractory prostate cancer. J Urol 2009; 181: 1091-7.
22. Olmos D, Arkenau HT, Ang JE et al.: Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience. Ann Oncol 2009; 20: 27-33.
23. Goodman OB Jr, Symanowski JT, Loudyi A et al.: Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer. Clin Genitourin Cancer 2011; 9: 31-8.
24. Okegawa T, Nutahara K, Higashihara E: Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer. J Urol 2008; 180: 1342-7.
25. www.uroweb.org/fileadmin/tx_eauguidelines/2009/Full/RCC.pdf
26. Gervais DA, McGovern FJ, Arellano RS et al.: Radiofrequency ablation of renal cell carcinoma. Part 1: Indications, results, and role in patient management over a 6-year period and ablation of 100 tumors. AJR Am J Roentgenol 2005; 185: 64-71.
27. Gradilone A, Iacovelli R, Cortesi E et al.: Circulating Tumor Cells and “Suspicious Objects” Evaluated Through CellSearch(R) in Metastatic Renal Cell Carcinoma. Anticancer Res 2011; 31: 4219-21.
28. Bluemke K, Bilkenroth U, Meye A et al.: Detection of circulating tumor cells in peripheral blood of patients with renal cell carcinoma correlates with prognosis. Cancer Epidemiol Biomarkers Prev 2009; 18: 2190-4.
29. http://www.onkologia.org.pl/ Krajowy Rejestr Nowotworów
30. Daneshmand S, Quek ML, Stein JP et al.: Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. J Urol 2004; 172: 2252-5.
31. Naoe M, Ogawa Y, Takeshita K et al.: Use of the CellSearch Circulating Tumor Cell Test for monitoring urothelial cancer: two case reports of metastatic urothelial cancer. South Med J 2008; 101: 439-41.
32. Rink M, Chun FK, Minner S et al.: Detection of circulating tumour cells in peripheral blood of patients with advanced non-metastatic bladder cancer. BJU Int 2011; 107: 1668-75.
33. Gallagher DJ, Milowsky MI, Ishill N et al.: Detection of circulating tumor cells in patients with urothelial cancer. Ann Oncol 2009; 20: 305-8.
34. Okegawa T, Hayashi K, Hara H et al.: Immunomagnetic quantification of circulating tumor cells in patients with urothelial cancer. Int J Urol 2010; 17: 254-8.
35. Flaig TW, Wilson S, van Bokhoven A et al.: Detection of circulating tumor cells in metastatic and clinically localized urothelial carcinoma. Urology 2011; 78: 863-7.
36. Minetta C, Liu: Circulating Tumor Cells: Prognosis, Prediction, and the Liquid Biopsy Breast Diseases: A Year Book_Quarterly 2012; 22, 4.
otrzymano: 2012-01-25
zaakceptowano do druku: 2012-02-29

Adres do korespondencji:
*Piotr L. Chłosta
Department of Urology, Holly Cross Cancer Centre
Artwińskiego Str. 3, 25-734 Kielce
tel.: +48 (41) 367-47-74
e-mail: piotr.chlosta@onkol.kielce.pl

Postępy Nauk Medycznych 4/2012
Strona internetowa czasopisma Postępy Nauk Medycznych